• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

检查点抑制剂治疗：免疫相关不良事件管理。

Checkpoint inhibitor therapy: Immune-related adverse event management.

机构信息

Lori Davis and Mary Beth Casselbury are triage nurses, and Sharon Wilson is a clinical nurse leader at the Lipson Cancer Institute in Rochester, N.Y.

出版信息

Nursing. 2024 Nov 1;54(11):26-33. doi: 10.1097/NSG.0000000000000083. Epub 2024 Oct 18.

DOI:10.1097/NSG.0000000000000083
PMID:39497665
Abstract

Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.

摘要

癌症的免疫检查点抑制剂治疗与多种免疫相关毒性的高患病率相关。免疫相关不良事件 (irAE) 可在治疗期间的任何时候以及治疗后 3 个月内发生。本文讨论了检查点抑制剂治疗，并描述了实施患者教育计划的情况，该计划侧重于识别免疫疗法 irAE 及其毒性。

相似文献

1
Checkpoint inhibitor therapy: Immune-related adverse event management.检查点抑制剂治疗：免疫相关不良事件管理。
Nursing. 2024 Nov 1;54(11):26-33. doi: 10.1097/NSG.0000000000000083. Epub 2024 Oct 18.
2
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素：法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
3
Toxicity in the era of immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗时代的毒性。
Front Immunol. 2024 Aug 23;15:1447021. doi: 10.3389/fimmu.2024.1447021. eCollection 2024.
4
Management of immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关皮肤不良反应的管理。
Thorac Cancer. 2020 Feb;11(2):488-492. doi: 10.1111/1759-7714.13275. Epub 2019 Dec 9.
5
Management of immune checkpoint inhibitor-related adverse events: A review of case reports.免疫检查点抑制剂相关不良反应的管理：病例报告综述。
Thorac Cancer. 2020 Mar;11(3):498-504. doi: 10.1111/1759-7714.13315. Epub 2020 Jan 22.
6
Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.接受免疫检查点抑制剂治疗患者的免疫治疗相关毒性管理
JAMA. 2021 Feb 2;325(5):482-483. doi: 10.1001/jama.2020.17308.
7
Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events.因免疫检查点抑制剂相关不良事件住院的转移性癌症患者生存率较低。
Immunotherapy. 2025 Apr;17(5):339-346. doi: 10.1080/1750743X.2025.2492541. Epub 2025 Apr 23.
8
Use of glucocorticoids in the management of immunotherapy-related adverse effects.糖皮质激素在免疫治疗相关不良反应管理中的应用。
Thorac Cancer. 2020 Oct;11(10):3047-3052. doi: 10.1111/1759-7714.13589. Epub 2020 Sep 6.
9
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.多国癌症支持治疗协会（MASCC）2020 年关于检查点抑制剂引起的严重胃肠道和肝脏毒性管理的临床实践建议。
Support Care Cancer. 2020 Dec;28(12):6129-6143. doi: 10.1007/s00520-020-05707-3. Epub 2020 Aug 27.
10
The Current and Future of Biomarkers of Immune Related Adverse Events.免疫相关不良事件生物标志物的现状与未来
Immunol Allergy Clin North Am. 2025 May;45(2):223-249. doi: 10.1016/j.iac.2025.01.010.

引用本文的文献

1
Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study.PD-1抑制剂治疗患者免疫相关甲状腺不良事件的临床表现及危险因素：一项病例对照研究
Front Immunol. 2025 Apr 28;16:1581057. doi: 10.3389/fimmu.2025.1581057. eCollection 2025.